BioSpace News Archive

Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that Humana is the fifth national payor in the US to cover focused ultrasound treatment for medication-refractory essential tremor.

Hangzhou Qihan Biotech Co., Ltd. today announced the successful completion of a pre-Series B financing exceeding $16 million funded by a new investor, Zhejiang Industrial Fund Co., Ltd., with participation from other existing investors.

Vibrant Wellness introduces the Toxin Genetics Test, a cutting-edge addition to its suite of advanced functional lab tests.

Coya Therapeutics, Inc. today announced licensing of the exclusive, worldwide rights of a proprietary Exosome Engineering Technology from CMU with potential applications across multiple indications, including neurodegeneration, autoimmune, and oncology.

Co-Diagnostics, Inc. announced today that Co-Diagnostics will be hosting a booth and presenting at the 6th Advances in Circulating Tumor Cells (“ACTC”) conference.

The Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) and US Medical Innovations, LLC (USMI) are pleased to announce today a ground-breaking achievement in surgical and robotic technology.

Faron Pharmaceuticals Ltd. is pleased to announce the appointment of Ms. Christine Roth and Dr. Marie-Louise Fjällskog as Non-Executive Directors of the Company with immediate effect following the passing of all resolutions put to shareholders of the Company at the Extraordinary General Meeting held earlier.

Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento” or “Company”) announced the consummation on September 21, 2023, of the previously announced sale to Scilex Holding Company (Nasdaq: SCLX, “Scilex”) of certain securities that Sorrento held in Scilex.

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the achievement of two milestones for its xenotransplantation programs in September: the second transplant of a UHeart™ xenoheart into a living person, and a 61-day study of the UThymoKidney™ xenokidney and thymus in a human pre-clinical model.

Pfizer Inc. (NYSE: PFE) shared today it has broadened its portfolio of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) following a favorable vote for ABRYSVO™ [Respiratory Syncytial Virus Vaccine], the company’s bivalent RSV prefusion F (RSVpreF) vaccine, as a maternal immunization.